A large part of her work is follow-up for chronic conditions like diabetes or hypertension, but she also does general primary care.“ I always say if you're lucky enough
2. or greater who have at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.
A warning that aliskiren-containing medications are contraindicated with angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or renal impairment because of the risk of
diabetes outpatient self-management training,. outpatient intravenous insulin treatment,. histocompatibility testing,. home prothrombin time/international normalized ratio monitoring for anticoagulation management,.
North Dakota, for Community-Based Diabetes Initiative Program. The North Dakota chapter received a second award for its diabetes prevention program in high-risk communities.
The FDA is investigating reports of possible increased risk of pancreatitis and precancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes.
31, 2015. Canaglifozin (Invokana) tablets, to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. ... It should not be used in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment or end-stage
QD: News Every Day--Teens with type 2 diabetes likely to need combination therapy sooner. ... A majority of teenagers with type 2 diabetes may require combination treatment or insulin therapy within a few years of diagnosis, researchers concluded.
This update covers approval of a sodium-glucose co-transporter 2 inhibitor for diabetes, a once-daily long-acting beta-adrenergic agonist (LABA) for chronic obstructive pulmonary disease (COPD), and a ... Empagliflozin (Jardiance) to treat type 2
This update also covers a risk evaluation and mitigation strategy for liraglutide and approval of a new PCSK9 inhibitor.